Mats Blom
Chairman at EGETIS THERAPEUTICS AB
Net worth: 2 M $ as of 2024-04-29
Network origin in Mats Blom first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 27 | |
| Public Company | Pharmaceuticals: Major | 24 | |
| Public Company | Pharmaceuticals: Major | 20 | |
Swedish Orphan International Holding AB
 Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets.
14
| Extinct | Pharmaceuticals: Major | 14 |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.
13
| Holding Company | Biotechnology | 13 |
| Public Company | Biotechnology | 11 | |
| Public Company | Biotechnology | 10 | |
| Public Company | Computer Peripherals | 6 | |
Auris Medical AG
 Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland.
4
| Subsidiary | Medical Specialties | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Mats Blom via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Public Communications Contact Investor Relations Contact | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| GENMAB A/S | Pharmaceuticals: Major | Director/Board Member Chairman | |
Q-Med AB
 Q-Med AB Medical SpecialtiesHealth Technology Q-Med AB specializes in aesthetic and corrective solutions. It develops and manufactures brand management for aesthetic and corrective treatments, whereas its portfolio is based on the company’s patented technology, NASHA, for the production of stabilise of non-animal hyaluronic acid. The firm offers portfolio including the brands Restylane, Emervel, Azzalure, Dysport, Deflux, Solesta, and Durolane are other products improving patients’ health in the corrective field. The company was founded by Bengt Agerup on June 17, 1985 and is headquartered in Uppsala, Sweden. | Medical Specialties | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| MEDIVIR AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Director/Board Member | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| ALK-ABELLÓ A/S | Biotechnology | Director/Board Member Director of Finance/CFO | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree Undergraduate Degree | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| Stockholm School of Economics | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree Masters Business Admin Masters Business Admin Masters Business Admin | |
| University of Uppsala | College/University | Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Undergraduate Degree | |
| University of Aarhus | College/University | Corporate Officer/Principal Masters Business Admin Undergraduate Degree | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree | |
Envirotainer AB
 Envirotainer AB Containers/PackagingProcess Industries Envirotainer AB provides cold chain solutions for the pharmaceutical supply chain. It offers active cold chain services, qualification services, shipment set up services, technical support, post-shipment analysis and telemetry solution. The company was founded in 1985 and is headquartered in Sollentuna, Sweden. | Containers/Packaging | Director/Board Member Corporate Officer/Principal | |
Melacure Therapeutics AB
 Melacure Therapeutics AB Pharmaceuticals: MajorHealth Technology Melacure Therapeutics AB develops and manufactures pharmaceutical products. Its products are used for treatment of obesity, irritable bowel syndrome, inflammation, and sexual dysfunction. The company was founded in 1998 and is located in Uppsala, Sweden. | Pharmaceuticals: Major | Chief Executive Officer General Counsel | |
Organon Pharma (UK) Ltd.
 Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Royal Institute of Technology | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| University of Lund | College/University | Corporate Officer/Principal Graduate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree Masters Business Admin Undergraduate Degree Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder Private Equity Investor | |
| The European Molecular Biology Laboratory | College/University | Corporate Officer/Principal Doctorate Degree | |
| University of Gothenburg | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Corporate Officer/Principal | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director of Finance/CFO Director/Board Member General Counsel | |
Swedish Orphan Biovitrum International AB
 Swedish Orphan Biovitrum International AB Pharmaceuticals: MajorHealth Technology Swedish Orphan Biovitrum International AB develops, manufactures, and sells pharmaceutical products and drugs. It offers patients and partners an international network specializing in the development, marketing and distribution of orphan drugs. The company is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Sales & Marketing | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Chairman Chief Executive Officer President Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Founder | |
| AVT Business School A/S | College/University | Chairman Masters Business Admin | |
Nexttobe AB
 Nexttobe AB Investment ManagersFinance Nexttobe AB focuses on growth equity investments in healthcare, medical devices, and specialty pharmaceutical companies. It is a venture capital/private equity firm that invests in technology and consumer companies. The company was founded by Bengt Ågerup in 2011 and is headquartered in Uppsala, Sweden. | Investment Managers | Chairman Chief Tech/Sci/R&D Officer | |
Rare Thyroid Therapeutics International AB
 Rare Thyroid Therapeutics International AB BiotechnologyHealth Technology Rare Thyroid Therapeutics International AB provides thyroid therapeutics research services. The company is headquartered in Stockholm, Sweden. | Biotechnology | Chairman Founder Chief Executive Officer | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer | |
| Active Security Trading AB | Director/Board Member Director/Board Member Chairman | ||
| Actinova AB | Director/Board Member Director/Board Member Director/Board Member |
Statistics
International
| Sweden | 24 |
| Denmark | 11 |
| United States | 5 |
| United Kingdom | 5 |
| Switzerland | 4 |
Sectoral
| Health Technology | 31 |
| Consumer Services | 13 |
| Finance | 4 |
| Commercial Services | 3 |
| Process Industries | 2 |
Operational
| Director/Board Member | 541 |
| Corporate Officer/Principal | 171 |
| Independent Dir/Board Member | 134 |
| Chairman | 121 |
| Chief Executive Officer | 86 |
Most connected contacts
| Insiders | |
|---|---|
| Somu Subramaniam | 48 |
| Alain Munoz | 38 |
| Peter Sjöstrand | 35 |
| Hugo Slootweg | 34 |
| Bo Jesper Hansen | 34 |
| Alf Gunnar Martin Nicklasson | 31 |
| Eva Nilsagård | 30 |
| Folke Per-Olof Wallström | 30 |
| Catherine Moukheibir | 29 |
| Maha Katabi | 28 |
| Ulf Arne Wiinberg | 26 |
| Hilde Hermansen Steineger | 24 |
| Anders Gersel Pedersen | 24 |
| Rosemary Crane | 23 |
| Jørgen Lindegaard | 22 |
- Stock Market
- Insiders
- Mats Blom
- Company connections
